natgillin/translations-raw huggingface dataset:
Method as claimed in any of the preceding claims, characterized in that said stirring element (104) is a passive emulsion forming means (104) operating by inertia upon stirring of the container (1) 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje je element (104) za miješanje pasivno sredstvo koje vrši svoje djelovanje nakon miješanja spremnika (1) i djeluje po inerciji.
Reaction mixture was heated at reflux for 5 minutes, then several iodine crystals were added keeping vigorous reflux to start the reaction. 
Reakcijska se smjesa grije 5 minuta uz refluks, te se zatim doda nekoliko kristala joda uz održavanje snažnog refluksa kako bi započela reakcija.
In another embodiment of the present invention, the therapeutic antibody is pertuzumab and the chemotherapeutic agent is a taxane, particularly docetaxel or paclitaxel, or an anthracycline, particularly doxorubicin, epirubicin, daunorubicin or valrubicin, more particularly doxorubicin. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što terapijsko je protutijelo pertuzumab, a kemoterapijsko sredstvo je taksan, osobito docetaksel ili paklitaksel, ili antraciklin, osobito doksorubicin, epirubicin, daunorubicin ili valrubicin.
On the basis of the data set out above, Isomer B is believed to have the 2S, 3S, 11bR configuration, which corresponds to Formula (Ia): 
Na osnovu gore navedenih podataka smatra se da Izomer B ima 28,3S,11bR konfiguraciju, što je odgovarajuće za Formulu (Ia): CHO CH,O
characterised in that the solvent system comprises a mixture of polar solvents, wherein then mixture of polar solvents comprises a straight or branched chain aliphatic alcohol with 1 to 5 carbon atoms and an aliphatic nitrile with 1 to 3 carbon atoms. 
(iii) dovođenje smjese iz koraka (1i) u doticaj s vodikom; naznačen time što sustav otapala sadrži smjesu polarnih otapala, gdje ta smjesa polarnih otapala obuhvaća alifatske alkohole ravnog ili razgranatog lanca s 1 do 5 atoma ugljika i alifatski nitril s 1 do 3 atoma ugljika.
a Tyr residue corresponding to position 245 of the a2 integrin amino acid sequence set forth in SEQ ID NO:8 or position 93 of the a2 integrin I domain amino acid sequence set forth in SEQ ID NO:11; 
Tyr ostatak koji odgovara položaju 245 u a2 integrin sekvenci aminokiselina prema SEQ ID NO:8 ili položaj 93 u domeni I a2 integrin sekvenci aminokiselina prema SEQ ID NO:11;
The aqueous composition arising from the process can be lyophilised for distribution, and the lyophilised material can eventually be reconstituted with an aqueous carrier for administration to patients. 
Vodeni sastav koji nastaje iz procesa može se liofilizirati za distribuciju, a liofilizirani materijal se eventualno može rekonstituirati s vodenim nosiocem za davanje pacijentima.
An isolated nucleic that encodes an antibody of any one of claims 1 to 7. An antibody of any one of claims 1 to 7 for use in a method for specifically depleting IgE-producing B-cells, the method comprising administering to a mammal a therapeutically effective amount of said anti-IgE/M1' antibody. 
Protutijelo prema bilo kojem zahtjevu od 1 do 11, naznačeno time, da se upotrebljava u postupku za specifično iscrpljivanje B-stanica koje proizvode IgE, gdje postupak obuhvaća primjenu terapeutski djelotvorne količine spomenutog anti-IgE/M1’ protutijela na sisavcu, pri čemu protutijelo po želji ima ADCC-djelotvornost.
Unfortunately, the use of nicotinic acid as a therapeutic is partially limited by a number of associated, adverse side-effects. 
Na nesreću, uporaba nikotinske kiseline kao terapeutika je djelomično ograničena brojnim pridruženim neželjenim nuz- efektima.
The collection according to claim 9, wherein said antibodies or functional fragments thereof comprise HCDR1 regions from the respective HCDR1 region depicted in figure 34. 
Zbirka u skladu s patentnim zahtjevom 9, naznačena time što navedena protutijela, ili njihovi funkcionalni fragmenti, sadrže područja HCDRI iz odgovarajućeg područja HCDRI, opisanog na slici 34.
An isolated antibody having the ability of binding to a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-10 and 35-79 and mediating inhibition of proliferation of cells expressing a protein comprising the amino acid sequence of SEQ ID NO: 2 and/or are characterized by association of a protein comprising the amino acid sequence of SEQ ID NO: 2 with the cell surface. 
HR P20180485 T1 PATENTNI ZAHTJEVI Antitijelo koje se vezuje za aminokiselinsku sekvencu sa SEK ID BR: 2 1 koje posreduje u inhibiciji proliferacije stanica, gdje spomenute stanice eksprimiraju protein koji sadrži aminokiselinsku sekvencu sa SEK ID BR: 2 i/ili su naznačene vezivanjem proteina koji sadrži aminokiselinsku sekvencu sa SEK ID BR: 2 sa njihovom staničnom površinom.
The packaging plank according to claim 8, wherein said containers are selected from the group consisting of cans, food cans, glass jars, cardboard boxes of the carton or Tetrapack® type. 
Uzorak ambalažnog pakiranja u skladu s bilo kojim od zahtjeva 12 do 14, naznačen time, da su navedeni spremnici (2) odabrani iz skupine koja se sastoji od limenki, konzervi, staklenki, kartonskih kutija tetraedarskog tipa ili tetrapaka Đ.
The JNK inhibitor sequence of any of claims 1 to 2, wherein the JNK inhibitor sequence binds c-jun amino terminal kinase (JNK). 
JNK inhibicijska sekvenca prema zahtjevu 1, naznačena time, da JNK inhibicijska sekvenca veže c-jun amino terminalnu kinazu (JNK).
A compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein: 
Spoj formule (II): > > m (nI ou rm» za hor HR P20100229 T1 ili njegova farmaceutski prihvatljiva sol, naznačen time da:
A succinate salt as claimed in any of claims 1-5 or a pharmaceutically acceptable salt as claimed in claim 6, for use in the treatment of metastatic non-small-cell lung cancer with CNS metastases. 
Spojevi formule (I), ili njegova farmaceutski prihvatljiva sol, za upotrebu u liječenju metastatskog nesitnostaničnog raka pluća prema patentnom zahtjevu 12, naznačeno time što, metastaze su metastaze na mozgu.
A compound of Formula (III): or a pharmaceutically acceptable salt thereof, wherein: 
Tvar formule III ili njena farmaceutski prihvatljiva sol, pri čemu
The matches are located alongside the box. 
Å ibice se nalaze uzduž kutije.
Step 1: reaction of an acyl chloride of formula (III) with an alkyl benzene of formula (IV) to yield the corresponding compound (V): whereby LG is a leaving group; 
navedeni proces sadrži korake: korak 1: reakcija acil klorida formule (III) s alkil benzenom formule (TV) da se dobije odgovarajući spoj (V): OS os (it
Process according to claim 1, wherein the nitro group is present in an aliphatic or cycloaliphatic compound and the base is diisopropylethylamine. 
Postupak u skladu s patentnim zahtjevima 1-7, naznačen time, da je nitro skupina nazočna u alifatskom ili cikcloalifatskom spoju a lužina je diizopropilctilamin.
means for processing the data delivered by said detecting and/or monitoring means and for determining the clotting time of said fluid medium. A device according to claim 17 characterised in that said property of said fluid medium is the position of the front of said fluid medium in each of said regions and/or its velocity. 
- uređaja za obradu podataka koje daje navedeni uređaj za detekciju i/ili praćenje i za određivanje vremena koagulacije navedenog fluidnog medija, gdje navedeni optički uređaj također mjeri ili očitava karakteristike kontrole kvalitete u mikrofluidičkom uređaju.
a distributor plate (7, 8, 90, 104) which at one side is in contact with the dosing pistons; characterised in that the distributor plate (7, 8, 90, 104) is in contact with two or more hydraulic piston (6, 102) at its other side for displacing the distributor plate for actuating the dosing pistons (21). 
- > raspodjela ploča (7, 8, 90, 104) koja je s jedne sirane u doticalu s dozirnim klinovima; naznačena time šio je raspodjelna ploča (7, 8, 90, 104) u doticaju s dva ili više hidraulička klipa (6, 102) na svojoj drugoj strani radi pomicanja raspodjelne ploče za pokretanje dozirnih klipova (21).
Alternatively, R9a and R9b together with the nitrogen atom to which they are attached form or, the above groups are unsubstituted or substituted by 1 to 3 Q2 substituent(s) which may be the same or different; and Q2 are independently selected from fluorine, chlorine, methyl or amino. 
(b) ciklobutilC, galkilna ili 6- do 12-eročlana spirociklička skupina C,galkil, gdje gore navedene skupine nisu supstituirane ili su supstituirane s 1 do 3 supstituenta, koji mogu biti isti ili različiti i bira ih se između Q', a jedan ili više ugljika u navedenom ciklobutilu mogu biti zamijenjeni jednim atomom kisika; alternativno,
Recombinant FSH according to claim 1 or 2 wherein from 10% to 15% of the total sialylation is a2,6-sialylation. Recombinant FSH according to any preceding claim having a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 6 mol/mol to 15 mol/mol. 
Farmaceutski pripravak koji sadrži rFSH uključujući a2,3-sialilaciju i a2,6-sialilaciju gdje 60% ili više od ukupne sialilacije je a2,3-sialilacija i od 5 do 40% od ukupne sialilacije je a2,6-sialilacija; te ima sadržaj sijalinske kiseline [izražen terminom omjera molova sijalinske kiseline prema molovima proteina] od 10 mol/mol do 16 mol/mol.
Component (C) and the optionally present component (D), which serve to achieve the breaking strength of at least 500 N which is necessary according to the invention may furthermore also optionally serve as additional matrix materials. 
Nadalje mogu također komponente (C) i po potrebi prisutna komponenta (D), koje služe za postizanje prijelomne čvrstoće od najmanje 500 N, potrebne prema izumu, služiti već kao dodatni materijali za matricu.
TLC analysis (silica, ethyl acetate) showed only very minor amounts of starting material remained. 
TLC analiza (silicij, etil acetat) je pokazala samo neznatne količine zaostalih početnih materijala.
A method of preparing a compound according claim 1, comprising reacting an intermediate compound of formula (A7), (B7) or (C7): 
Postupak za dobivanje spoja prema zahtjevu 1, naznačen time da navedeni postupak sadrži korak pretvaranja intermedijarnog spoja s formulom (B7):
The multispecific antigen-binding molecule of claim 3, wherein the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site which comprises an L chain variable region consisting of any one of the amino acid sequences selected from the following (c1) to (c10), or an antigen-binding site functionally equivalent thereto: 
(b) mjesta vezanja antigena uključena u treći polipeptid i četvrti polipeptid, obuhvaćaju mjesto vezanja antigena koje obuhvaća varijabilno područje L-lanca koje se sastoji od bilo koje od aminokiselinskih sekvenci odabranih od sljedećih (c1) do (c10):
The invention therefore relates to an aqueous pharmaceutical preparation comprising an active ingredient in a therapeutically effective and pharmacologically acceptable amount and alkoxylated fat, where the active ingredient is selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of the pyridine residue of roflumilast or salts thereof. 
farmakološki prihvatljivoj količini te alkoksiliranu mast, pri čemu je aktivni sastojak izabran iz skupine koju čine roflumilast, soli roflumilasta, N-oksid piridinskog ostatka roflumilasta i njegove soli.
After the drying in the drying equipment 71, the process for the manufacture of a veneer according to the process of the invention may be terminated. 
Nakon sušenja u opremi za sušenje 71, može se završiti postupak za proizvodnju furnira, koji postupak je u skladu s ovim izumom.
Natrium Chloride at a concentration ranging from about 3400 to about 3600 mg/L, most preferably about 3500 mg/L. 
-Natrijev klorid u koncentraciji u rasponu od oko 3400 do oko 3600 mg/L, najpoželjnije oko 3500 mg/L.
is condensed with 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride of formula III 
CH, podvrgava reakciji kondenzacije s 1-klorkarbonil-4-piperidinopiperidin-hidrokloridom formule III
In another aspect, the crenolanib or a pharmaceutically acceptable salt thereof is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulphonate and crenolanib succinate. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu je crenolanib crenolanib bezilat, crenolanib fosfat, crenolanib laktat, crenolanib hidroklorid, crenolanib citrat, crenolanib acetat, crenolanib toluensulfonat i crenolanib sukcinat.
The extrudate preferably has a mean diameter of from about 0.1 to about 12 mm, about 0.1 to about 2.5 mm,about 0.2 to about 6 mm, 0.5 to about 3 mm, about 0.5 mm to about 2 mm, or about 1 mm to about 2 mm. 
Farmaceutski proizvod prema zahtjevu 9, naznačen time da je naltrekson hidroklorid u količini od oko 2 mg do oko 12 mg, od oko 2 mg do oko 8 mg i/ili da čestice naltrekson hidroklorida sadrže više od 90%, poželjno više od 95% hidrofobnog materijala.
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and 
(a) najmanje jedan polietilen oksid koji ima, bazirano na reološkim mjerenjima, približnu molekulsku težinu od najmanje 1,000,000; 1
Use according to Claim 2 or Claim 3, wherein, in the compound of formula la, the structural fragment is in the R - configuration at the C-atom to which R1a is attached. 
Uporaba prema zahtjevu 2 ili zahtjevu 3, naznačena time da, u spoju s formulom 1a, strukturni fragment [image] je u R-konfiguraciji na C-atomu na koji je spojen R1a.
If this is required for a special application, the ground product can have a grain size distribution with d50 less than 20 um and d90 less than 100 um, or d50 less than 5 um and d90 less than 20 um, or d50 less than 0.1 um and d90 less than 2 um. 
Postupak sukladno zahtjevu 8, 9, ili 10, naznačen time što ternesit cement ima distribuciju veličine zrna d50 manje od 20 um i d90 manje od 100 um, ili d50 manje od 5 um i d90 manje od 20 um, ili 450 manje od 0.1 um i d90 manje od 2 um.
A compound of formula I according to claim 1, wherein hetaryl I is and hetaryl II is a bicyclic ring system containing 1 to 4 heteroatoms as defined in claim 1. 
[image] i hetaril II je biciklički sustav prstena, koji ima od 1 do 4 heteroatoma kao što je definirano u zahtjevu 1.
HCl (1.1 eq) under stirring. 
uz miješanje.
The micro chip (10) as claimed in claim 1, wherein there is a gap between the reaction chamber (11) base and the heater (12), and said gap is ranging from about 0.2 mm to about 0.7 mm. 
Mikročip (10) prema zahtjevu 1, pri čemu se između reakcijske komore (11) baze i grijača (12) nalazi praznina veličine od 0,2 mm do 0,7 mm.
The compound according to embodiment 66, wherein R1 is CH2Ph and R2 is CH2CH2Ph. 
Spoj sukladno patentnom zahtjevu 1, naznačeno time da je spoj hidroklorid di-sol.
The method may also according to another aspect of the present invention comprise a second step of filtering water soluble organics from the water, such as an purification of methanol in a second membrane-filter. 
Metoda u skladu s patentnim zahtjevom 13, nadalje obuhvaća drugi korak filtriranja u vodi topivih organskih tvari iz vode, kao što je pročišćavanje metanola u drugom membranskom filtru.
performing said nucleic acid amplification reaction, thereby producing a DNA amplicon molecule; and 
(c) izvođenje reakcije amplifikacije nukleinske kiseline, pri čemu se dobiva amplikon DNA molekule; 1
Method as claimed in claim 1, wherein said compression of said powdered product dose is substantially uniformly carried out within a closed compression chamber (11) with a shape complementary to that of said tablet (C). 
Postupak sukladno zahtjevu 1, pri čemu se kompresija doze praškastog proizvoda u osnovi izvodi u zatvorenoj kompresijskoj komori (11) oblika komplementarnog navedenoj tableti (C).
(A2a) a phenyl-substituted lower alkenyl group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group, or (A2b) a halogen-substituted phenyl group); and n represents an integer of 1 to 6. 
(A2a) fenil-supstituiranu skupinu niži alkenil s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (supstituentima) na fenilnoj skupini, ili (A2b) halogen-supstituiranu fenilnu skupinu).
In some embodiments, the hemihydrate has an X-ray powder diffraction pattern characteristic of Form III comprising peaks, in terms of 2θ, at about 13.7° and about 14.9°. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima uzorak difrakcije praha X-zrakama koji sadrži pikove, u značenju 28, na oko 13.7% i0ko14.9".
the algorithm is trained using the gene expression data obtained in claim 5; or 
(ili) algoritam se obučava upotrebom podataka o ekspresiji gena dobivenih u patentnom zahtjevu 5; ili
vi) repeating steps ii) to v) to build up a stack of interfolded gloves within the recess. 
HR P20180218 T1 vi) ponavljanje koraka ii) do v) sa slijedećim rukavicama da se napravi snop međusobno presavijenih rukavica unutar navedenog udubljenja.
The mean estimated potency of the Reference Material ST1P01/r-hIL-18BP resulted to be equal to 895869 U/ml with a CV% of 17.6. 
Srednji utvrđeni potencijal Referentnog Materijala STIPO1/r-hIL-18BP bio je jednak vrijednosti od 895869 U/ml s CV% od 17.6.
A peptide as claimed in claim 1, having an amino acid sequence in accordance with SEQ ID NO: 44. 
Peptid, sukladno patentnom zahtjevu 1, sadrži amino kiselinski spoj sukladno sa SEQ ID NO:11
This invention also provides a unit dose of 0.5 ml of an aqueous pharmaceutical solution which contains in solution 20 mg glatiramer acetate and 20 mg mannitol for use in reducing frequency of relapses in a human patient afflicted with relapsing, remitting multiple sclerosis (RRMS). 
Jedinična doza prema bilo kojem od patentnih zahtjeva 1-4, naznačena time, da jest za uporabu u smanjivanju učestalosti relapsa kod ljudskog pacijenta koji boluje od relapsno-remitentnog tijeka multiple skleroze (RRMS).
The thickness and/or the type of conducting material may be varied to achieve virtually any desired degree of heat transfer. 
Debljina i/ili tip provodnog materijala mogu se mjenjati tako da se postigne praktično makoji željeni stupanj transfera topline.
The coupling system according to claim 1, wherein the first and/or second circumferential recess of the adapter piece respectively extend along a circumferential angle of approx. 270°. 
Sustav za spajanje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se prvo i/ili drugo udubljenje na obodu (4, 5) adapterskog dijela (1) odgovarajuće pruža pod obodnim kutem od otprilike 270".
The antisense compound for use according to any of claims 1 or 3-9 or the use of an antisense compound according to any of claims 2-9, wherein the antisense compound is administered both systemically and to the central nervous system and wherein the systemic administration and the administration into the central nervous system are performed at different times. 
Protusmisleni spoj za uporabu prema bilo kojem od patentnih zahtjeva I ili 3 - 9 ili uporaba protusmislenog spoja prema bilo kojem od patentnih zahtjeva 2 - 9, naznačena time što se protusmisleni spoj primjenjuje i sistemski i u središnji živčani sustav, te pri čemu se sistemska primjena i primjena u središnji živčani sustav provode u različito vrijeme.
In some embodiments, the coating in the second dosage composition can be designed to ensure that the release of the proton pump inhibitor is delayed from 120 to at least 240 minutes following oral administration. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što obloga u pripravku druge doze odgađa otpuštanje inhibitora protonske pumpe sa 120 na najmanje 240 minuta nakon peroralne primjene.
A system as claimed in claim 1, wherein the first end of the coupling is arranged to provide a surface surrounding an exposed length of cable sheath for receiving an inductive component. 
Sistem kao što se zahtijeva u bilo kojem zahtjevu 1 do 16, naznačen time, da je prvi kraj (5) spajanja (1) raspoređen za osiguravanje površine koja okružuje izloženu dužinu cjevastog dijela kabela (35) za primanje induktivne komponente (51).
(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone in its racemic or enantiomeric form for use in treatment or prophylaxis of ischemia/reperfusion injury. 
(6-hidroksi-2,5,7,8-tetrametiljkroman-2-il)(4-(2-hidroksietil)piperazin-1-il) metanon, naznačen time, da je u svojem racemičnom ili enantiomernom obliku u svrhu liječenja ili profilakse ishemije/povreda reperfuzije.
A process for preparing an oxycodone salt composition having less than 25 ppm 14-hydroxycodeinone, which process comprises the steps of: 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 15 ppm.
A conjugate comprising an antibody of any one of claims 1-7 coupled to a therapeutic agent, preferably a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji se sastoji od antitijela suglasno bilo kojem zahtjevu 1-11, povezanog sa nekim terapeutskim agensom, poželjno toksinom ili radioizotopom, lijekom ili nekim citotoksičnim agensom.
Packaging unit according to claim 1, wherein the embossing has a depth in the range of 0.1 - 1.5 mm, preferably in the range of 0.5 - 1.0 mm. 
Jedinica za pakiranje prema zahtjevu 1, naznačena time da reljefni tisak ima dubinu u rasponu od 0.1 - 1.5 mm, poželjno u rasponu od 0.5 - 1.0 mm.
The method of claim 20, wherein the genomic locus of interest comprises a T cell receptor alpha locus. 
Postupak za ciljanu modifikaciju genomskog lokusa od interesa u pluripotentnoj stanici štakora, koji sadrži:
Reconstitution is performed by adding 5 ml Water for Injection, with subsequent dilution in normal saline before i.v. 
Rekonstitucija se izvodi dodavanjem 5 ml vode čistoće za injekciju, uz naknadno razrjeđivanje u normalnoj slanoj otopini prije i.v.
The composition of claim 1, wherein the muscarinic receptor agonist is pilocarpine. 
Sastav 12 patentnog zahtjeva 1, pri čemu je agonist muskarinskih receptora pilokarpin.
The halogen atom represents a fluorine, chlorine, bromine or iodine atom; 
Atom halogena predstavlja atom fluora, klora, broma ili joda.
or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. 
Q ča ili njegova farmaceutski prihvatljiva sol, ili solvat od toga.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća terapijski učinkovitu količinu tvari iz bilo kojeg od patentnih zahtjeva 1-3 i farmaceutski prihvatljivi nosač.
The process of claim 11 further comprising coupling an amino-terminal protected Asp having a protected carboxyl side chain to a Trp-Pro dipeptide through the Trp of the dipeptide and removing the amino-terminal protecting group from the Asp to form the 4-6 eptifibatide sequence. 
Postupak prema patentnom zahtjevu 11, naznačen time, da nadalje sadrži kopuliranje amino-terminalno zaštićenog Asp ostatka koji ima zaštićeni karboksilni postrani lanac na Trp-Pro dipeptid preko Trp ostatka dipeptida i uklanjanje amino-terminalne zaštitne skupine iz Asp ostatka da nastane fragment 4-6 eptifibatida.
Inhibition of tankyrases of compounds of the formula I 
Broj objave europskog patenta:
a counter having indicia, the counter being rotatable within the body in increments about the longitudinal axis of the body; 
brojača koji ima oznake, brojač (203) bivajući okretan unutar tijela (1) u inkrementima oko uzdužne osi (214) tijela (1);
The antibody of claim 1, wherein the antibody binds to an epitope comprising one or both of amino acids N224 or K248 of SEQ ID NO:13. 
ID BR.: 31. Protutijelo prema patentnom zahtjevu 1, naznačeno time, da se protutijelo veže na epitop koji se sastoji od jedne ili obje aminokiseline N224 ii K248 od SEK.